ArticleNeurology2025
Midlife Vascular Risk Factors, Parkinson Disease, and Parkinson Disease-Dementia: The ARIC Study.
Article in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
objectivesVascular risk factors (VRFs) such as smoking, hypertension, obesity, and diabetes are associated with dementia, but their importance in Parkinson disease (PD) and PD-dementia (PDD) is less well understood. Previous studies demonstrated that smoking may be protective of PD, but its role in PDD is unclear. The primary objective was to examine the association between midlife VRFs and the risk of developing PD and PDD in older adults.
methodsThe prospective, longitudinal community-based cohort Atherosclerosis Risk in Communities study recruited Black and White adults (45-64 years old) from Jackson, MS; Forsyth County, NC; Minneapolis suburbs, MN; and Washington County, MD, in 1987-1989. VRFs (smoking status, hypertension, obesity, hypercholesterolemia, and diabetes) were measured at the baseline visit. PD cases were retrospectively adjudicated through 2016 by reviewing participant medications, self-reported physician-made diagnoses, and hospitalization and death surveillance data. Dementia cases were adjudicated using in-person and telephone-based cognitive testing, informant interviews, and hospitalization codes. PDD cases were defined as an adjudicated PD diagnosis followed by an adjudicated dementia diagnosis. Cox proportional hazard models, adjusted for age, race, sex, education level, and APOE ε4 status, evaluated midlife VRFs together in association with PD, with separate models evaluating PD without dementia, PDD, and dementia without PD.
resultsAmong 13,875 individuals with nonmissing VRF and outcome data with up to 30 years of follow-up (25% Black, 54% female), 179 developed PD at a mean age of 73.4 years, 94 developed PDD at a mean age of 79.2 years, and 1,791 developed dementia without PD at a mean age of 79.7 years. Midlife current smoking (hazard ratio [HR] 0.36, 95% CI 0.21-0.61) was significantly associated with a lower PD rate, independent of other risk factors and demographics. Midlife current smoking was also significantly associated with a lower rate of PDD (HR 0.41, 95% CI 0.18-0.95). Other VRFs were not associated with either PD or PDD. DISCUSSION: Smoking status in midlife was associated with lower rates of PD and PDD, but other VRFs had no association with PD or PDD. Further studies should evaluate changes of these VRFs over the life course and explore mechanisms for the observed associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.